Dukes Iain D. has filed 17 insider transactions across 3 companies since June 2023.
Most recent transaction: a grant/award of 231336 shares of Traws Pharma, Inc. ($TRAW) on March 08, 2026.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 8, 2026 | Traws Pharma, Inc. | $TRAW | Dukes Iain D. | Chief Executive Officer | A | Stock Option (right to buy) | 231336 | $0.00 | 231,336.0000 | 8,818,859 | 9999.99% | 2.62% |
| Dec. 12, 2025 | Traws Pharma, Inc. | $TRAW | Dukes Iain D. | Chief Executive Officer | A | Stock Option (right to purchase) | 147771 | $0.00 | 147,771.0000 | 8,818,859 | 9999.99% | 1.68% |
| Dec. 12, 2025 | Traws Pharma, Inc. | $TRAW | Dukes Iain D. | Chief Executive Officer | A | Common Stock | 36943 | $0.00 | 171,130.0000 | 8,818,859 | 27.53% | 0.42% |
| Oct. 12, 2025 | Traws Pharma, Inc. | $TRAW | Dukes Iain D. | Chief Executive Officer | A | Stock Option (right to purchase) | 64839 | $0.00 | 64,839.0000 | 8,818,859 | 9999.99% | 0.74% |
| June 13, 2025 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Dukes Iain D. | Director | A | Deferred Restricted Stock Unit | 135092 | $0.00 | 135,092.0000 | 322,868 | 9999.99% | 41.84% |
| April 1, 2024 | Traws Pharma, Inc. | $TRAW | Dukes Iain D. | Executive Chairman | A | Common Stock | 67500 | $0.00 | 134,187.0000 | 841,738 | 101.22% | 8.02% |
| June 11, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Dukes Iain D. | Director | A | Deferred Restricted Stock Unit | 98607 | $0.00 | 98,607.0000 | 266,220 | 9999.99% | 37.04% |
| June 7, 2024 | ImageneBio, Inc. | $IMA | Dukes Iain D. | Not found | A | Stock Option (Right to Buy) | 17520 | $0.00 | 17,520.0000 | 0 | 9999.99% | 0.00% |
| April 1, 2024 | Traws Pharma, Inc. | $TRAW | Dukes Iain D. | Executive Chairman | A | Series C Preferred Stock | 4801 | $0.00 | 4,995.7367 | 841,738 | 2466.89% | 0.57% |
| April 1, 2024 | Traws Pharma, Inc. | $TRAW | Dukes Iain D. | Executive Chairman | A | Common Stock | 1645100 | $0.00 | 1,779,287.0000 | 841,738 | 1225.98% | 100.00% |
| April 1, 2024 | Traws Pharma, Inc. | $TRAW | Dukes Iain D. | Executive Chairman | A | Stock Option (right to purchase) | 3802890 | $0.00 | 3,802,890.0000 | 841,738 | 9999.99% | 100.00% |
| April 1, 2024 | Traws Pharma, Inc. | $TRAW | Dukes Iain D. | Executive Chairman | A | Series C Preferred Stock | 195 | $0.00 | 4,995.7367 | 841,738 | 4.05% | 0.02% |
| April 1, 2024 | Traws Pharma, Inc. | $TRAW | Dukes Iain D. | Executive Chairman | A | Common Stock | 66687 | $0.00 | 1,711,787.0000 | 841,738 | 4.05% | 7.92% |
| April 1, 2024 | Traws Pharma, Inc. | $TRAW | Dukes Iain D. | Executive Chairman | A | Common Stock | 67550 | $0.00 | 1,779,287.0000 | 841,738 | 3.95% | 8.03% |
| March 1, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Dukes Iain D. | Director | A | Deferred Restricted Stock Unit | 100000 | $0.00 | 100,000.0000 | 235,131 | 9999.99% | 42.53% |
| Feb. 20, 2024 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Dukes Iain D. | Director | P | Common Stock | 32000 | $9.15 | 54,000.0000 | 235,131 | 145.45% | 13.61% |
| June 6, 2023 | IOVANCE BIOTHERAPEUTICS, INC. | $IOVA | Dukes Iain D. | Director | A | Deferred Restricted Stock Unit | 103911 | $0.00 | 103,911.0000 | 213,694,000 | 9999.99% | 0.05% |